Cargando…

A review of minodronic acid hydrate for the treatment of osteoporosis

Minodronic acid hydrate was the first bisphosphonate developed and approved for osteoporosis treatment in Japan. With regard to inhibition of bone resorption, minodronic acid hydrate is 1000 times more effective than etidronic acid and 10–100 times more effective than alendronic acid. Clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanishima, Shinji, Morio, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578444/
https://www.ncbi.nlm.nih.gov/pubmed/23440003
http://dx.doi.org/10.2147/CIA.S23927
_version_ 1782260018085625856
author Tanishima, Shinji
Morio, Yasuo
author_facet Tanishima, Shinji
Morio, Yasuo
author_sort Tanishima, Shinji
collection PubMed
description Minodronic acid hydrate was the first bisphosphonate developed and approved for osteoporosis treatment in Japan. With regard to inhibition of bone resorption, minodronic acid hydrate is 1000 times more effective than etidronic acid and 10–100 times more effective than alendronic acid. Clinical trials conducted to date have focused on postmenopausal female patients suffering from primary osteoporosis. In these trials, 1 mg of oral minodronic acid hydrate was administrated once daily, and a significant increase was observed in lumbar-spine and hip-joint bone density 1–2 years after administration. All markers of bone metabolism urinary collagen type 1 cross-linked N-telopeptide, urinary free deoxypyridinoline, serum bone alkaline phosphatase, and serum osteocalcin were decreased. The incidence rate of new vertebral and nonvertebral fractures was also decreased. Therefore, effectiveness in fracture prevention was confirmed. A form of minodronic acid (50 mg) requiring once-monthly administration has been developed and is currently being used clinically. A comparative study between this new formulation and once-daily minodronic acid (1 mg) showed no significant differences between the two formulations in terms of improvement rates in lumbar-spine and hip-joint bone density, changes in bone metabolism markers, or incidence of side effects. This indicates the noninferiority of the monthly formulation. Side effects such as osteonecrosis of the jaw or atypical femoral fractures were not reported with other bisphosphonates, although it is believed that these side effects may emerge as future studies continue to be conducted. On the basis of studies conducted to date, minodronic acid hydrate is considered effective for improving bone density and preventing fractures. We anticipate further investigations in the future.
format Online
Article
Text
id pubmed-3578444
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35784442013-02-22 A review of minodronic acid hydrate for the treatment of osteoporosis Tanishima, Shinji Morio, Yasuo Clin Interv Aging Review Minodronic acid hydrate was the first bisphosphonate developed and approved for osteoporosis treatment in Japan. With regard to inhibition of bone resorption, minodronic acid hydrate is 1000 times more effective than etidronic acid and 10–100 times more effective than alendronic acid. Clinical trials conducted to date have focused on postmenopausal female patients suffering from primary osteoporosis. In these trials, 1 mg of oral minodronic acid hydrate was administrated once daily, and a significant increase was observed in lumbar-spine and hip-joint bone density 1–2 years after administration. All markers of bone metabolism urinary collagen type 1 cross-linked N-telopeptide, urinary free deoxypyridinoline, serum bone alkaline phosphatase, and serum osteocalcin were decreased. The incidence rate of new vertebral and nonvertebral fractures was also decreased. Therefore, effectiveness in fracture prevention was confirmed. A form of minodronic acid (50 mg) requiring once-monthly administration has been developed and is currently being used clinically. A comparative study between this new formulation and once-daily minodronic acid (1 mg) showed no significant differences between the two formulations in terms of improvement rates in lumbar-spine and hip-joint bone density, changes in bone metabolism markers, or incidence of side effects. This indicates the noninferiority of the monthly formulation. Side effects such as osteonecrosis of the jaw or atypical femoral fractures were not reported with other bisphosphonates, although it is believed that these side effects may emerge as future studies continue to be conducted. On the basis of studies conducted to date, minodronic acid hydrate is considered effective for improving bone density and preventing fractures. We anticipate further investigations in the future. Dove Medical Press 2013 2013-02-15 /pmc/articles/PMC3578444/ /pubmed/23440003 http://dx.doi.org/10.2147/CIA.S23927 Text en © 2013 Tanishima and Morio, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Tanishima, Shinji
Morio, Yasuo
A review of minodronic acid hydrate for the treatment of osteoporosis
title A review of minodronic acid hydrate for the treatment of osteoporosis
title_full A review of minodronic acid hydrate for the treatment of osteoporosis
title_fullStr A review of minodronic acid hydrate for the treatment of osteoporosis
title_full_unstemmed A review of minodronic acid hydrate for the treatment of osteoporosis
title_short A review of minodronic acid hydrate for the treatment of osteoporosis
title_sort review of minodronic acid hydrate for the treatment of osteoporosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578444/
https://www.ncbi.nlm.nih.gov/pubmed/23440003
http://dx.doi.org/10.2147/CIA.S23927
work_keys_str_mv AT tanishimashinji areviewofminodronicacidhydrateforthetreatmentofosteoporosis
AT morioyasuo areviewofminodronicacidhydrateforthetreatmentofosteoporosis
AT tanishimashinji reviewofminodronicacidhydrateforthetreatmentofosteoporosis
AT morioyasuo reviewofminodronicacidhydrateforthetreatmentofosteoporosis